Investor Information

Our purpose is motivated by our vision. Every move we make is inspired and driven by the purpose to ‘care for every life’. We’re constantly seeking new and  innovative solutions to achieve that goal.

Investor Presentation

Q1_FY20 Investor Presentation

07th August 2019

Download
Q4_FY19 Investor Presentation

22nd May 2019

Download
Q3_FY19 Investor Presentation

06th February 2019

Download
Q2_FY19 Investor Presentation

05th November 2018

Download
 

The displayed data is not in real time and may have streaming delays.

Latest Press Release

29th July 2019

Alvotech and Cipla Gulf enter into a partnership for the Commercialization of key biosimilar in select emerging markets

Read More
25th July 2019

Cipla USA furthers AMR stewardship with acquisition of key anti-infective ZEMDRI™ (IV Plazomicin)

Read More
22nd July 2019

Cipla receives final approval for generic version of Gilead Sciences, Inc’s Letairis® (Ambrisentan Tabs, 5mg & 10mg)

Read More

Contact


Company Secretary

Cipla Limited
Tel: (022) 2482 6000  |   Fax: (022) 2482 6120
E-mail: cosecretary@cipla.com

Submit Query

Investor Relation

Naveen Bansal
Investor Relations
Tel: (022) 2482 6000
E-mail: Investor.Relations@cipla.com

Submit Query